FUJIFILM Pharma

MA - CambridgePharmaceutical4 H-1B visas (FY2023)

Focus: FUJIFILM Pharma is a newly established (2023) pharmaceutical division headquartered in Cambridge, MA, focusing on small-molecule inhibitors and lipid nanoparticle/liposome-based therapeutics across oncology, immunology, and infectious diseases.

Oncology Immunology Neurology Gastroenterology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About FUJIFILM Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow FUJIFILM Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A novel endoscopic imaging system that displays real-time oxygen saturation levels

Anastomotic Leak Rectum

N/A

Clinical Trials (1)

NCT07467980Endoscopic COlorectal Mucosal Evaluation of Oxygen Tension

N/A

Help build intelligence for FUJIFILM Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage division with diverse pipeline spanning 5 therapeutic areas (oncology, immunology, neurology, gastroenterology, infectious diseases) offering broad career development opportunities
Demonstrated commitment to talent acquisition with 100% H1B approval rate (4/4 approvals in 2023) and Cambridge headquarters positioning for biotech talent
Advanced-stage pipeline with 2 Phase 3 programs (T-614 and FKB327 in rheumatoid arthritis) providing near-term catalysts and regulatory visibility

Watch Out For

Newly founded division (2023) with limited public financial data, employee count unknown, and zero active job postings—raises questions about hiring freeze or organizational clarity
Heavy dependence on inherited/partnered assets (favipiravir, endoscopy devices) with unclear internal R&D capability or differentiated discovery engine

Generated by Claude from FUJIFILM Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DBT plus S-View

Breast Cancer

N/A

Clinical Trials (1)

NCT03491917Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer

N/A

DBT plus S-View

Breast Cancer

N/A

Clinical Trials (1)

NCT03501693Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study

N/A

FBP

Breast Cancer

N/A

Clinical Trials (1)

NCT03586583Fujifilm Feature Comparison Reader Study to Compare Old vs New Processing

N/A

Fujinon EC-450BI5 double-balloon colonoscope

Colorectal Cancer

N/A

Clinical Trials (1)

NCT01587872Double-balloon Colonoscopy to Increase Colonoscopy Completion Rate

N/A

EW10-EC02

Polyp Colorectal

N/A

Clinical Trials (1)

NCT04979962AI Colorectal Polyp Detection

N/A

Fuji Flim Processor VP-7000, Light Source BL-7000

Gastro-Intestinal Disorder

N/A

Clinical Trials (1)

NCT03440047Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim

N/A

Cognitive Computerized Training

Acquired Brain Injury

N/A

Clinical Trials (1)

NCT06130735Impact of Intensive Computerized Cognitive Training

N/A

Fujifilm SILVAMP TB LAM

Diagnosis of Tuberculosis in People Living With HIV

N/A

Clinical Trials (1)

NCT04089423FujiLAM Prospective Evaluation Trial

N/A

Standard X-Ray + CT

Wrist Injury

N/A

Clinical Trials (1)

NCT01927575Pilot Study Comparing Diagnostic Imaging Versus Tomosynthesis in Detection of Hip, Wrist or Tibia Injury

N/A

Colonoscopy

Lynch Syndrome

N/A

Clinical Trials (1)

NCT03344289Linked Color Imaging Versus High-definition White Light Endoscopy for the Detection of Polyps in Patients With Lynch Syndrome (LCI-LYNCH)

N/A

Endosonographic Elastography

Liver Fibrosis

N/A

FFDM Mammography

Breast Cancer

N/A

Clinical Trials (1)

NCT02156258Acquisition of Breast Mammography Images

N/A

Single Endoscopy Procedure

Endoscopy

N/A

Clinical Trials (1)

NCT02755285Study Comparing Blue Light Imaging (BLI) With Flexible Spectral-Imaging Color Enhancement (FICE)

N/A

FFDM Plus DBT

Breast Cancer

N/A

Clinical Trials (1)

NCT02692209A Multi-Reader Multi-Case Pivotal Trial

N/A

Whole Blood Donation

iPS Cell Manufacture and Banking

N/A

3Dimensional Mammography

Breast Cancer

N/A

Clinical Trials (1)

NCT01542814Collection of FUJIFILM's 3Dimensional Mammograms

N/A

Breast Cancer

N/A

Clinical Trials (1)

NCT01928992Pilot 3D Mammography Reader Study to Assess Breast Cancer Detection in 3D Versus 2D Digital Mammography

N/A

colonoscopy

Screening Colonoscopy

N/A

Clinical Trials (1)

NCT04894708Study on the Use of Artificial Intelligence (Fujifilm) for Polyp Detection in Colonoscopy

N/A

Standard Colonoscopy

Colorectal Cancer

N/A

Clinical Trials (1)

NCT05237310Comparing Detection of Standard Colonoscopy, CAD-EYE and Combined CAD-EYE and G-EYE® Aided Colonoscopy

N/A

FFDM Plus DBT

Breast Cancer

N/A

Clinical Trials (1)

NCT02685566Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program

N/A

FICE Image Acquisition followed by NBI Image Acquisition

Routine Endoscopy

N/A

Clinical Trials (1)

NCT02005393Study Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI)

N/A

FFDM Plus DBT

Breast Cancer

N/A

Clinical Trials (1)

NCT02511730Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone

N/A

DBT HR mode image acquisition

Routine Screening Mammography

N/A

Clinical Trials (1)

NCT07471750Acquisition and Clinical Image Evaluation of Fujifilm's High Resolution (HR) Digital Breast Tomosynthesis (DBT) Images.

N/A

FF-10850 Topotecan Liposome Injection

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT04047251A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

Phase 1

favipiravir

Infectious Disease

PHASE_1

Clinical Trials (1)

NCT06024421Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Phase 1

FF-10101-01

AML, Adult

PHASE_1

Clinical Trials (1)

NCT03194685Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

T-817MA

Healthy

PHASE_1

Clinical Trials (1)

NCT02693197PK Study of T-817 in Subjects With Hepatic Impairment

Phase 1

FF21101

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT02454010A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

Phase 1

FF-10832 Gemcitabine Liposome Injection

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT03440450A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

Phase 1

FF-10502-01

Solid Tumors

PHASE_1_2

Clinical Trials (1)

NCT02661542Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2

FF-10501-01

AML

PHASE_1_2

Clinical Trials (1)

NCT02193958Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

Phase 1/2

Favipiravir

COVID-19

PHASE_2

Clinical Trials (1)

NCT04358549Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

Phase 2

FF-10501-01

Myelodysplastic Syndrome (MDS)

PHASE_2

Clinical Trials (1)

NCT03486353A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

Phase 2

T-817MA-H

Alzheimer's Disease

PHASE_2

Clinical Trials (1)

NCT02079909Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

Phase 2

T-817MA

Mild Cognitive Impairment

PHASE_2

Clinical Trials (1)

NCT04191486Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Phase 2

Pembrolizumab

Advanced Urothelial Carcinoma

PHASE_2

T-817MA

Alzheimer's Disease

PHASE_2

Clinical Trials (1)

NCT00663936Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Phase 2

Favipiravir

Coronavirus Infection

PHASE_3

Clinical Trials (1)

NCT04373733Early Intervention in COVID-19: Favipiravir Verses Standard Care

Phase 3

human autologous synovial stem cells

Meniscus Injury

PHASE_3

Clinical Trials (1)

NCT05777967Efficacy and Safety of FF-31501 in Meniscus Tear Patients

Phase 3

T-614

Rheumatoid Arthritis

PHASE_3

FKB327

Arthritis, Rheumatoid

PHASE_3

Clinical Trials (1)

NCT02260791A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

Phase 3

FKB327

Arthritis, Rheumatoid

PHASE_3

Clinical Trials (1)

NCT02405780A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 39 clinical trials

Top TAs: Oncology, Immunology, Gastroenterology

H-1B (2023): 4 approvals

Therapeutic Area Focus

16 pipeline

3 pipeline

2 pipeline

2 pipeline

2 pipeline

Marketed

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo